NDT Advance Access published online on May 23, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl244
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Social Pharmacy, Pharmacoepidemiology & Pharmacotherapy, Groningen University for Drug Exploration (GUIDE), Groningen, The Netherlands
* To whom correspondence should be addressed. Background. Statins improve cardiovascular outcome, but less is known on the renal outcome. We, therefore, studied the relationship between the use of statins and urinary albumin excretion (UAE) and glomerular filtration rate (GFR) in two settings: a randomized controlled trial (RCT) and an observational cohort study, in which patients were included to study the impact of an elevated UAE on renal and cardiovascular prognosis. Methods. We used data from the Prevention of REnal and Vascular ENd-stage Disease Intervention trial (PREVEND-IT) and the PREVEND cohort study. The PREVEND-IT subjects (788 with a UAE 15-300 mg/day) received pravastatin 40 mg/day vs placebo and/or fosinopril 20 mg/day vs placebo in a 2 x 2 factorial-RCT design. Of the 3440 cohort subjects, 469 used statins during the 4-year follow-up period. Multivariate-regression adjusted for confounding factors and the propensity score was used to estimate the relation between statin use and UAE and GFR. Results. In the RCT, pravastatin did not change UAE or GFR, neither in fosinopril yes/no subgroups. In the observational cohort, statin use was associated with a rise in UAE (+12.1%), compared with statin non-use (+3.6%, P < 0.001). This rise was most pronounced in those on statins prior to the first screening [+24.8% (95% CI: 11.9-39.2)], those using statins >3 years [+18.5% (7.3-30.8)] and those with >1 or >2 defined daily doses (+15.7 and +17.3%, respectively). These differences remained significant after adjustment for relevant variables and propensity score. The rise in UAE could not be attributed to a higher dose or a specific statin. GFR fell in 4 years in both statin users and non-users (4.6 ± 13.5 and 2.4 ± 11.2, respectively). The fall in GFR between groups was not different after adjustment (P = 0.11). Conclusions. We conclude from the RCT data that statins do not lower UAE in subjects selected because of an elevated UAE instead of hyperlipidaemia. In the observational cohort study, the use of statins similarly was not associated with a fall in UAE; UAE instead increased. Statin treatment was not associated with a significant change in GFR in these subjects with only modestly impaired GFR.
Received April 3, 2006
Accepted April 5, 2006
Original Article
The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study
Jarir Atthobari 1,
Auke H. Brantsma 2,
Ron T. Gansevoort 2,
Sipke T. Visser 1,
Folkert W. Asselbergs 3,
Wiek H. van Gilst 3,
Paul E. de Jong 4,
Lolkje T. W. de Jong-van den Berg 1 *,
and
on behalf of PREVEND study group
2 Department of Internal Medicine, Division of Nephrology, Pharmacoepidemiology & Pharmacotherapy, Groningen University for Drug Exploration (GUIDE), Groningen, The Netherlands; University of Groningen and University Medical Center Groningen (UMCG), The Netherlands
3 Department of Clinical Pharmacology, Groningen University for Drug Exploration (GUIDE), Groningen, The Netherlands; University of Groningen and University Medical Center Groningen (UMCG), The Netherlands
4 Department of Internal Medicine, Division of Nephrology, Pharmacoepidemiology & Pharmacotherapy, Groningen University for Drug Exploration (GUIDE), Groningen, The Netherlands
Lolkje T. W. de Jong-van den Berg, E-mail: L.T.W.de.Jong-van.den.Berg{at}rug.nl
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Paulsen, C. Holm, J. N. Bech, J. Starklint, and E. B. Pedersen Effects of statins on renal sodium and water handling: Acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1556 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kolavennu, L. Zeng, H. Peng, Y. Wang, and F. R. Danesh Targeting of RhoA/ROCK Signaling Ameliorates Progression of Diabetic Nephropathy Independent of Glucose Control Diabetes, March 1, 2008; 57(3): 714 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Korantzopoulos, M. Elisaf, and H. J. Milionis Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease ready for prime time? Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2768 - 2774. [Full Text] [PDF]
|
|
|
|
|
|
J. Atthobari, R. T. Gansevoort, L. T. W. de Jong-van den Berg, and P. E. de Jong Reply Nephrol. Dial. Transplant., March 1, 2007; 22(3): 964 - 964. [Full Text] [PDF]
|
|
|
|
|
|
V. G. Athyros, A. Karagiannis, A. Kakafika, M. Elisaf, and Dimitri. P. Mikhailidis Statins and renal function. Is the compound and dose making a difference? Nephrol. Dial. Transplant., March 1, 2007; 22(3): 963 - 964. [Full Text] [PDF]
|
|